• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·AMGN
Held by 3 Gurus
Share

Amgen Inc. Stocks

$ 385.65Last Updated 18.09.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 208.14B

$ 385.65
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.1%

Change

+0.02%

Fund

CITADEL ADVISORS LLC

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.01%

Fund

Bridgewater Associates

Steven Cohen

Portfolio Weight (%)

0.0%

Change

-0.01%

Fund

Point72 Asset Management, L.P.

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.1%+0.02%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.01%
Steven CohenPoint72 Asset Management, L.P.0.0%-0.01%

Latest news

09.09.2026 17:04

Mid-cap biotech Dyne becomes collateral damage of another Novartis pipeline setback

09.09.2026 15:41

Morning in New York: Brent Puts Investors to the Test

08.09.2026 16:07

Pharmaceutical giant Novartis is on track for its worst slump in six years following a series of failed trials

08.09.2026 15:14

Morning in New York: The Oil Rally Continues

20.12.2025 03:43

Nine major pharma companies have made deals with Trump to lower drug prices

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of AMGN is 366 and suggests 5.03% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.09.2026 01:05

The Nasdaq set a new record for the first time since June, while the S&P 500 had its best day since August

22.09.2026 00:41

The ECB has launched the first digital euro settlements in the interbank market

21.09.2026 23:48

Meta shares are having their best month in 13 years, with the price at its highest level since October. Is it too late to buy?

21.09.2026 23:31

A $30 Trillion Market and the Risk of an Apocalypse: How Much Could Anthropic Be Worth? — An FT Analysis

21.09.2026 23:15

Amazon has blocked Meta's AI agent on its marketplace. What's the issue?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026